The Experts below are selected from a list of 56427 Experts worldwide ranked by ideXlab platform
Martínez Riera Roser - One of the best experts on this subject based on the ideXlab platform.
-
Uso terapeutico de isoflavonas de la soja en el trastorno por consumo de cocaína /
2020Co-Authors: Martínez Riera Roser, Universitat Autònoma De Barcelona. Departament De Psiquiatria I De MediAbstract:Departament responsable de la tesi: Departament de Psiquiatria i de Medicina Legal.El proyecto pretende valorar una nueva terapia en el tratamiento del trastorno por consumo de cocaína. Recientemente se ha descubierto que un inhibidor de la enzima aldehído deshidrogenasa-2 reduce el consumo de cocaína en animales (ALDH2). Se trata de un derivado de la daidzina-daidzeína, una de las isoflavonas que contiene la soja. Los extractos de soja y la daidzina-daidzeína se han utilizado para el tratamiento del alcoholismo en animales y humanos. Se considera de interés conocer si puede ser eficaz en el trastorno por consumo de cocaína y si interfiere en el metabolismo del acetaldehído. Se desarrollaron tres ensayos clínicos en humanos: uno de farmacocinética a dosis única de diferentes preparados de extracto de soja para elegir uno y ser usado en los otros ensayos; otro mecanístico para evaluar la interacción entre el extracto de soja y el alcohol; y un tercero exploratorio para valorar la eficacia de un inhibidor natural de la ALDH2 (daidzina-daidzeína) en pacientes con trastorno por consumo de cocaína. El objetivo del estudio era evaluar la eficacia de un inhibidor selectivo de la ALDH2 de origen natural (daidzina-daidzeína, contenida en extracto de soja) en el tratamiento del Trastorno por Consumo de Cocaína y conocer si interfiere en el metabolismo del acetaldehído. Con la administración concomitante de extracto de soja y alcohol, no se observó alteración de signos vitales ni efectos subjetivos o adversos; por otro lado, ningún voluntario afecto de Trastorno por consumo de cocaína adquirió abstinencia completa, pero se observó una alta retención al tratamiento, una disminución de la severidad del consumo en la escala Severity Dependence Scale (SDS) y mejoría del estado de salud física en distintas áreas del SF-36 Health Survey. Nuestros resultados demuestran la no interferencia de daidzina-daidzeína con el metabolismo del acetaldehído y sugieren una posible función reduciendo la gravedad del consumo de cocaína. Así, la comorbilidad alcohol-cocaína, no sería criterio de exclusión en el posible uso de daidzina-daidzeína como tratamiento del consumo de cocaína.The project aims to evaluate a new therapy in treating cocaine use disorder. Recently it was discovered that an inhibitor of the enzyme aldehyde deshidrogenada-2 (ALDH2) reduces cocaine use in animals. It is a derivative of daidzin-daidzein, one of the isoflavones contained in soy. Daidzin-daidzein and soy extracts have been associated with reductions of alcohol use in animals and humans. It is interesting to know whether it can be effective in cocaine use disorder and if it interacts in the metabolism of acetaldehyde. We carried out three clinical trials in humans: a single dose pharmacokinetics of different soy extract prepared to choose one to use in the other clinical trials; another mechanistic to assess the interaction between soy extract and alcohol; and a third exploratory to evaluate the efficacy of an inhibitor of aldehyde deshidrogenase-2 (daidzin-daidzein) in patients with a cocaine use disorder. The objective of the study was to evaluate the efficacy of an inhibitor of aldehyde deshidrogenase-2 (daidzin-daidzein, contained in soy extract) in the treatment of the cocaine use disorder and to know if interacts with the acetaldehyde metabolism. With the administration of soy extract and alcohol, it was not Observed Disturbance of the vital sings and subjective or adverse effects; on the other hand, no volunteer with cocaine use disorder reached hole abstinence, but a high retention in treatment, a decrease of the Severity Dependence Scale (SDS) and an improvement in the different areas of the SF-36 Health Survey was Observed. Our results demonstrate that daidzin-daidzein did not interfere in the acetaldehyde metabolism and suggest a possible function decreasing the severity of cocaine consumption. Cocaine-alcohol comorbidity, would not be an exclusion criteria in the possible use of daidzin-daidzein like a treatment for cocaine consumption
-
Uso terapeutico de isoflavonas de la soja en el trastorno por consumo de cocaína
2019Co-Authors: Martínez Riera RoserAbstract:El proyecto pretende valorar una nueva terapia en el tratamiento del trastorno por consumo de cocaína. Recientemente se ha descubierto que un inhibidor de la enzima aldehído deshidrogenasa-2 reduce el consumo de cocaína en animales (ALDH2). Se trata de un derivado de la daidzina-daidzeína, una de las isoflavonas que contiene la soja. Los extractos de soja y la daidzina-daidzeína se han utilizado para el tratamiento del alcoholismo en animales y humanos. Se considera de interés conocer si puede ser eficaz en el trastorno por consumo de cocaína y si interfiere en el metabolismo del acetaldehído. Se desarrollaron tres ensayos clínicos en humanos: uno de farmacocinética a dosis única de diferentes preparados de extracto de soja para elegir uno y ser usado en los otros ensayos; otro mecanístico para evaluar la interacción entre el extracto de soja y el alcohol; y un tercero exploratorio para valorar la eficacia de un inhibidor natural de la ALDH2 (daidzina-daidzeína) en pacientes con trastorno por consumo de cocaína. El objetivo del estudio era evaluar la eficacia de un inhibidor selectivo de la ALDH2 de origen natural (daidzina-daidzeína, contenida en extracto de soja) en el tratamiento del Trastorno por Consumo de Cocaína y conocer si interfiere en el metabolismo del acetaldehído. Con la administración concomitante de extracto de soja y alcohol, no se observó alteración de signos vitales ni efectos subjetivos o adversos; por otro lado, ningún voluntario afecto de Trastorno por consumo de cocaína adquirió abstinencia completa, pero se observó una alta retención al tratamiento, una disminución de la severidad del consumo en la escala Severity Dependence Scale (SDS) y mejoría del estado de salud física en distintas áreas del SF-36 Health Survey. Nuestros resultados demuestran la no interferencia de daidzina-daidzeína con el metabolismo del acetaldehído y sugieren una posible función reduciendo la gravedad del consumo de cocaína. Así, la comorbilidad alcohol-cocaína, no sería criterio de exclusión en el posible uso de daidzina-daidzeína como tratamiento del consumo de cocaína.The project aims to evaluate a new therapy in treating cocaine use disorder. Recently it was discovered that an inhibitor of the enzyme aldehyde deshidrogenada-2 (ALDH2) reduces cocaine use in animals. It is a derivative of daidzin-daidzein, one of the isoflavones contained in soy. Daidzin-daidzein and soy extracts have been associated with reductions of alcohol use in animals and humans. It is interesting to know whether it can be effective in cocaine use disorder and if it interacts in the metabolism of acetaldehyde. We carried out three clinical trials in humans: a single dose pharmacokinetics of different soy extract prepared to choose one to use in the other clinical trials; another mechanistic to assess the interaction between soy extract and alcohol; and a third exploratory to evaluate the efficacy of an inhibitor of aldehyde deshidrogenase-2 (daidzin-daidzein) in patients with a cocaine use disorder. The objective of the study was to evaluate the efficacy of an inhibitor of aldehyde deshidrogenase-2 (daidzin-daidzein, contained in soy extract) in the treatment of the cocaine use disorder and to know if interacts with the acetaldehyde metabolism. With the administration of soy extract and alcohol, it was not Observed Disturbance of the vital sings and subjective or adverse effects; on the other hand, no volunteer with cocaine use disorder reached hole abstinence, but a high retention in treatment, a decrease of the Severity Dependence Scale (SDS) and an improvement in the different areas of the SF-36 Health Survey was Observed. Our results demonstrate that daidzin-daidzein did not interfere in the acetaldehyde metabolism and suggest a possible function decreasing the severity of cocaine consumption. Cocaine-alcohol comorbidity, would not be an exclusion criteria in the possible use of daidzin-daidzein like a treatment for cocaine consumption
Universitat Autònoma De Barcelona. Departament De Psiquiatria I De Medi - One of the best experts on this subject based on the ideXlab platform.
-
Uso terapeutico de isoflavonas de la soja en el trastorno por consumo de cocaína /
2020Co-Authors: Martínez Riera Roser, Universitat Autònoma De Barcelona. Departament De Psiquiatria I De MediAbstract:Departament responsable de la tesi: Departament de Psiquiatria i de Medicina Legal.El proyecto pretende valorar una nueva terapia en el tratamiento del trastorno por consumo de cocaína. Recientemente se ha descubierto que un inhibidor de la enzima aldehído deshidrogenasa-2 reduce el consumo de cocaína en animales (ALDH2). Se trata de un derivado de la daidzina-daidzeína, una de las isoflavonas que contiene la soja. Los extractos de soja y la daidzina-daidzeína se han utilizado para el tratamiento del alcoholismo en animales y humanos. Se considera de interés conocer si puede ser eficaz en el trastorno por consumo de cocaína y si interfiere en el metabolismo del acetaldehído. Se desarrollaron tres ensayos clínicos en humanos: uno de farmacocinética a dosis única de diferentes preparados de extracto de soja para elegir uno y ser usado en los otros ensayos; otro mecanístico para evaluar la interacción entre el extracto de soja y el alcohol; y un tercero exploratorio para valorar la eficacia de un inhibidor natural de la ALDH2 (daidzina-daidzeína) en pacientes con trastorno por consumo de cocaína. El objetivo del estudio era evaluar la eficacia de un inhibidor selectivo de la ALDH2 de origen natural (daidzina-daidzeína, contenida en extracto de soja) en el tratamiento del Trastorno por Consumo de Cocaína y conocer si interfiere en el metabolismo del acetaldehído. Con la administración concomitante de extracto de soja y alcohol, no se observó alteración de signos vitales ni efectos subjetivos o adversos; por otro lado, ningún voluntario afecto de Trastorno por consumo de cocaína adquirió abstinencia completa, pero se observó una alta retención al tratamiento, una disminución de la severidad del consumo en la escala Severity Dependence Scale (SDS) y mejoría del estado de salud física en distintas áreas del SF-36 Health Survey. Nuestros resultados demuestran la no interferencia de daidzina-daidzeína con el metabolismo del acetaldehído y sugieren una posible función reduciendo la gravedad del consumo de cocaína. Así, la comorbilidad alcohol-cocaína, no sería criterio de exclusión en el posible uso de daidzina-daidzeína como tratamiento del consumo de cocaína.The project aims to evaluate a new therapy in treating cocaine use disorder. Recently it was discovered that an inhibitor of the enzyme aldehyde deshidrogenada-2 (ALDH2) reduces cocaine use in animals. It is a derivative of daidzin-daidzein, one of the isoflavones contained in soy. Daidzin-daidzein and soy extracts have been associated with reductions of alcohol use in animals and humans. It is interesting to know whether it can be effective in cocaine use disorder and if it interacts in the metabolism of acetaldehyde. We carried out three clinical trials in humans: a single dose pharmacokinetics of different soy extract prepared to choose one to use in the other clinical trials; another mechanistic to assess the interaction between soy extract and alcohol; and a third exploratory to evaluate the efficacy of an inhibitor of aldehyde deshidrogenase-2 (daidzin-daidzein) in patients with a cocaine use disorder. The objective of the study was to evaluate the efficacy of an inhibitor of aldehyde deshidrogenase-2 (daidzin-daidzein, contained in soy extract) in the treatment of the cocaine use disorder and to know if interacts with the acetaldehyde metabolism. With the administration of soy extract and alcohol, it was not Observed Disturbance of the vital sings and subjective or adverse effects; on the other hand, no volunteer with cocaine use disorder reached hole abstinence, but a high retention in treatment, a decrease of the Severity Dependence Scale (SDS) and an improvement in the different areas of the SF-36 Health Survey was Observed. Our results demonstrate that daidzin-daidzein did not interfere in the acetaldehyde metabolism and suggest a possible function decreasing the severity of cocaine consumption. Cocaine-alcohol comorbidity, would not be an exclusion criteria in the possible use of daidzin-daidzein like a treatment for cocaine consumption
W A Rocca - One of the best experts on this subject based on the ideXlab platform.
-
alcohol and tobacco consumption as risk factors for alzheimer s disease a collaborative re analysis of case control studies
1991Co-Authors: Amy Borenstein Graves, Cornelia M Van Duijn, V Chandra, Laura Fratiglioni, A Heyman, Anthony F Jorm, Emre Kokmen, K Kondo, J A Mortimer, W A RoccaAbstract:textabstractA meta-analysis, involving the secondary analysis of original data from 11 case-control studies of Alzheimer's disease, is presented for alcohol consumption and cigarette smoking. Five studies included in the meta-analysis of alcohol consumption. Alcohol consumption was computed in terms of average weekly intake, measured in ounces of 'pure alcohol'. This variable was categorized into tertiles to represent low, medium and high intake. Analyses showed no excess estimated risk of Alzheimer's disease for any level of alcohol intake. Smoking was analysed in three different manners: (1) lifetime prevalence of smoking (ever/never)--this included eight studies; (2) amount smoked (less than or equal to one pack per day versus more than one pack per day)--this included seven studies; and (3) pack-years--including four studies. A statistically significant inverse association between smoking and Alzheimer's disease was Observed at all levels of analysis, with a trend towards decreasing risk with increasing consumption (p(trend) = 0.0003). A propensity towards a stronger inverse relation was Observed among patients with a positive family history of dementia, but the difference between this group and the group with no such history was not statistically significant. Although the Observed Disturbance in nicotinic receptor function in Alzheimer's disease may provide an explanation for these findings, possible biases related to the selection or survival of study subjects cannot be fully ruled out at this time. Prospective, community-based studies of incident cases of Alzheimer's disease are needed to document in detail the smoking history, age of onset of disease and survival of patients and cognitively intact people by smoking status.
-
alcohol and tobacco consumption as risk factors for alzheimer s disease a collaborative re analysis of case control studies
1991Co-Authors: Amy Borenstein Graves, V Chandra, Laura Fratiglioni, A Heyman, Anthony F Jorm, Emre Kokmen, K Kondo, J A Mortimer, Cornelia M Van Duijn, W A RoccaAbstract:A meta-analysis, involving the secondary analysis of original data from 11 case-control studies of Alzheimer's disease, is presented for alcohol consumption and cigarette smoking. Five studies included in the meta-analysis of alcohol consumption. Alcohol consumption was computed in terms of average weekly intake, measured in ounces of 'pure alcohol'. This variable was categorized into tertiles to represent low, medium and high intake. Analyses showed no excess estimated risk of Alzheimer's disease for any level of alcohol intake. Smoking was analysed in three different manners: (1) lifetime prevalence of smoking (ever/never)--this included eight studies; (2) amount smoked (less than or equal to one pack per day versus more than one pack per day)--this included seven studies; and (3) pack-years--including four studies. A statistically significant inverse association between smoking and Alzheimer's disease was Observed at all levels of analysis, with a trend towards decreasing risk with increasing consumption (p(trend) = 0.0003). A propensity towards a stronger inverse relation was Observed among patients with a positive family history of dementia, but the difference between this group and the group with no such history was not statistically significant. Although the Observed Disturbance in nicotinic receptor function in Alzheimer's disease may provide an explanation for these findings, possible biases related to the selection or survival of study subjects cannot be fully ruled out at this time. Prospective, community-based studies of incident cases of Alzheimer's disease are needed to document in detail the smoking history, age of onset of disease and survival of patients and cognitively intact people by smoking status.
Amy Borenstein Graves - One of the best experts on this subject based on the ideXlab platform.
-
alcohol and tobacco consumption as risk factors for alzheimer s disease a collaborative re analysis of case control studies
1991Co-Authors: Amy Borenstein Graves, Cornelia M Van Duijn, V Chandra, Laura Fratiglioni, A Heyman, Anthony F Jorm, Emre Kokmen, K Kondo, J A Mortimer, W A RoccaAbstract:textabstractA meta-analysis, involving the secondary analysis of original data from 11 case-control studies of Alzheimer's disease, is presented for alcohol consumption and cigarette smoking. Five studies included in the meta-analysis of alcohol consumption. Alcohol consumption was computed in terms of average weekly intake, measured in ounces of 'pure alcohol'. This variable was categorized into tertiles to represent low, medium and high intake. Analyses showed no excess estimated risk of Alzheimer's disease for any level of alcohol intake. Smoking was analysed in three different manners: (1) lifetime prevalence of smoking (ever/never)--this included eight studies; (2) amount smoked (less than or equal to one pack per day versus more than one pack per day)--this included seven studies; and (3) pack-years--including four studies. A statistically significant inverse association between smoking and Alzheimer's disease was Observed at all levels of analysis, with a trend towards decreasing risk with increasing consumption (p(trend) = 0.0003). A propensity towards a stronger inverse relation was Observed among patients with a positive family history of dementia, but the difference between this group and the group with no such history was not statistically significant. Although the Observed Disturbance in nicotinic receptor function in Alzheimer's disease may provide an explanation for these findings, possible biases related to the selection or survival of study subjects cannot be fully ruled out at this time. Prospective, community-based studies of incident cases of Alzheimer's disease are needed to document in detail the smoking history, age of onset of disease and survival of patients and cognitively intact people by smoking status.
-
alcohol and tobacco consumption as risk factors for alzheimer s disease a collaborative re analysis of case control studies
1991Co-Authors: Amy Borenstein Graves, V Chandra, Laura Fratiglioni, A Heyman, Anthony F Jorm, Emre Kokmen, K Kondo, J A Mortimer, Cornelia M Van Duijn, W A RoccaAbstract:A meta-analysis, involving the secondary analysis of original data from 11 case-control studies of Alzheimer's disease, is presented for alcohol consumption and cigarette smoking. Five studies included in the meta-analysis of alcohol consumption. Alcohol consumption was computed in terms of average weekly intake, measured in ounces of 'pure alcohol'. This variable was categorized into tertiles to represent low, medium and high intake. Analyses showed no excess estimated risk of Alzheimer's disease for any level of alcohol intake. Smoking was analysed in three different manners: (1) lifetime prevalence of smoking (ever/never)--this included eight studies; (2) amount smoked (less than or equal to one pack per day versus more than one pack per day)--this included seven studies; and (3) pack-years--including four studies. A statistically significant inverse association between smoking and Alzheimer's disease was Observed at all levels of analysis, with a trend towards decreasing risk with increasing consumption (p(trend) = 0.0003). A propensity towards a stronger inverse relation was Observed among patients with a positive family history of dementia, but the difference between this group and the group with no such history was not statistically significant. Although the Observed Disturbance in nicotinic receptor function in Alzheimer's disease may provide an explanation for these findings, possible biases related to the selection or survival of study subjects cannot be fully ruled out at this time. Prospective, community-based studies of incident cases of Alzheimer's disease are needed to document in detail the smoking history, age of onset of disease and survival of patients and cognitively intact people by smoking status.
Faajeng Lin - One of the best experts on this subject based on the ideXlab platform.
-
real time ip position controller design with torque feedforward control for pm synchronous motor
1997Co-Authors: Faajeng LinAbstract:A digital signal processor (DSP)-based permanent magnet (PM) synchronous motor (SM) drive with a proposed recursive least-square (RLS) estimator and real-time integral-proportional (IP) position controller is introduced in this study. First, the rotor inertia constant, the damping constant, and the disturbed load torque of the synchronous motor are estimated by the proposed RLS estimator, which is composed of an RLS estimator and a torque observer. Next, the IP position controller is real-time designed according to the estimated rotor parameters, to match the time-domain command tracking specifications. Then, the Observed Disturbance torque is fed forward, to increase the robustness of the synchronous motor drive.
